US EditionInfarmed Caution for "Individual" Medicinal Products with Ketiapine
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
The difficulty of supplying these drugs, especially in the form of a prolonged release package, is due to obstacles in the main manufacturing unit in Greece.
The Infarmed warned against the shortage of medicines with ketiapine, used in the treatment of schizophrenia, depression and bipolar episodes, recommending to doctors who consider therapeutic alternatives and medications that limit the availability of a month of treatment. According to the National Medicines and Health Products Authority (Infarmed), the difficulty of supplying these medicines, especially in the form of a prolonged release packag…
The Infarmed - National Medicines and Health Products Authority warned, this Friday, for the "hard supply" of medicinal products with ketiapine, due to "constrictions in the main unit of manufacture". "The medicinal products containing ketiapine, mainly in the pharmaceutical form of a prolonged release tablet, have difficulty supply due to restrictions in the main factory unit, located in Greece, which affect most companies present on the market…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
